Viewing Company Valeant Pharmaceuticals | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Valeant Pharmaceuticals Stock Symbol: VRX-T

Last Price Recorded: $11.6100 on 2017-04-24

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-04-12 DON'T BUY Christine Poole

Has new management which are trying to sell off some assets and get the prices they want. Trying to change the way they operate in terms of not buying companies that actually do internal R&D, but that is difficult because they don’t have a lot of cash, but have a lot of debt. There is not a lot of visibility, which is why the stock is trading where it is. Drug pricing is now being highly scrutinized, and she doesn’t see that going away.


Price:
$12.760
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
No
2017-04-12 COMMENT John O'Connell, CFA

This is a tough call. The guy that is running the business is doing a good job. The problem is that they’ve got a debt, and what is the pricing power of this company going to be. As they sell assets in a less exuberant market than what they were purchasing them, he doesn’t think they are getting the same value proposition for the sale that offsets the amount of debt that they are able to retire. He is not touching this.


Price:
$12.760
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
No
2017-03-20 COMMENT Lyle Stein

Struggling with massive amounts of debt, which was acquired when everything was looking great. The problem was, the assets they bought they probably overpaid for by using cheap paper. $30 billion is a lot of debt and he doesn’t know how they overcome it. He doesn’t like bottom fishing.


Price:
$14.200
Subject:
CANADIAN
Bias:
CAUTIOUS
Owned:
No
2017-03-16 DON'T BUY Zachary Curry

He would be negative on this. It is a company with a business model of increasing drug prices, by materially high amounts. This has bitten off a lot of debt in order to go on their acquisition binges. If interest rates rise and they need to get financing, it is going to be extremely difficult.


Price:
$15.030
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
No
2017-03-09 COMMENT Teal Linde

Thinks this is getting beaten down because in their latest quarterly results, they guided that revenues would be down 8% this year. The company has 3 divisions, and in each of them the revenues were down year-over-year. Those 3 divisions have 15 subdivisions, and only 2 of them had revenues go up. The current is still running against this company. They have a huge debt load.


Price:
$15.620
Subject:
NORTH AMERICAN - LARGE/MID CAPS
Bias:
UNKNOWN
Owned:
Unknown
2017-03-08 DON'T BUY William Chin

This had a big fall in 2015-2016, and it hasn’t formed a base yet. Don’t be a hero. Wait for a credible rally to develop first.


Price:
$16.030
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
UNKNOWN
Owned:
Unknown
2017-03-03 WAIT David Cockfield

He was never a fan of this company. It is back into a reasonable PE area. Thinks there are still questions about just how profitable this company can be. The actual corporate plan has changed totally. You should really wait and see how well their new plan is working.


Price:
$17.460
Subject:
CANADIAN & ETF's
Bias:
UNKNOWN
Owned:
No
2017-02-01 DON'T BUY Brendan Caldwell

Concordia (CXR-T) or Valeant (VRX-T)? He wouldn’t pick either because whenever you have accounting irregularities, that never gets better, especially in Canada. This sector is under so much heat right now. The US president has really focused in on even legitimate drug companies and there is going to be a lot of scrutiny. doesn’t think either will survive.


Price:
$17.880
Subject:
CANADIAN VALUE
Bias:
OPTIMISTIC
Owned:
No
2017-01-24 COMMENT Don Lato

If an aggressive investor looking for speculation, this is probably a decent speculation. On the other hand, if you are a more conservative investor, there are too many things that can go wrong. The main problem is the debt load they have. They have a debt to equity ratio of over 7 to 1. It is still making money, but it has a gun to its head with respect to selling some assets to pay down some of that debt. Also, president Trump has a target on the pharmaceutical industry.


Price:
$17.910
Subject:
NORTH AMERICAN
Bias:
OPTIMISTIC
Owned:
Unknown
2016-12-30 DON'T BUY Paul Harris, CFA

This is under a lot of pressure. One of the problems with a company like this is that analysts are using EBITDA, and for companies like this they should be using free cash. Thinks this is what caused a lot of the disaster. Doesn’t see any reason why you need to own this.


Price:
$19.470
Subject:
NORTH AMERICAN/GLOBAL
Bias:
UNKNOWN
Owned:
No
2016-12-29 PAST TOP PICK Jerome Hass

(A Top Pick Feb 8/16. Up 84.67%.) Short. (A Pairs trade with Mylan (MYL-Q.)


Price:
$19.160
Subject:
CANADIAN MID-CAPS & LONG/SHORT STRATEGIES
Bias:
UNKNOWN
Owned:
No
2016-12-22 DON'T BUY Benj Gallander

It has had the crap beat out of it.  They have had all kinds of difficulties.  He is always very wary of stocks that keep going up just because they are taking over other companies.  This is what hit this one.  He is not considering it at this point in time. 


Price:
$19.210
Subject:
CONTRARIAN and VALUE INVESTING
Bias:
CONTRARIAN
Owned:
No
2016-12-15 SELL Andy Nasr

He avoided it throughout.  He would get rid of it because of the tremendous debt on the balance sheet.  If they divested and reduced debt then he might be interested.  He would hang on if you can handle the downside.


Price:
$18.150
Subject:
REITS, GLOBAL & MACRO STRATEGY
Bias:
SELECTIVE
Owned:
No
2016-12-14 COMMENT Michael Smedley

This is going to continue to be problematic, not only because of its own financial situation, but also certain environmentalists. There is a possibility it could be acquired, which would be a plus. He does not favour the stock. (See Top Picks.)


Price:
$18.790
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:
Unknown
2016-11-07 DON'T BUY Don Vialoux

This does not have a period of seasonal strength. The technicals do not look good. It recently broke down through support once again. When you have a stock that is underperforming the market and is in a downward trend, you don’t want to be there.


Price:
$25.510
Subject:
TECHNICAL ANALYSIS & SEASONAL INVESTING
Bias:
UNKNOWN
Owned:
Unknown
Showing 1 to 15 of 687 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.